AVID BIOSERVICES INC (CDMO) Fundamental Analysis & Valuation

NASDAQ:CDMO • US05368M1062

Current stock price

12.49 USD
+0.01 (+0.08%)
Last:

This CDMO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CDMO Profitability Analysis

1.1 Basic Checks

  • CDMO had negative earnings in the past year.
  • In the past year CDMO had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: CDMO reported negative net income in multiple years.
  • Of the past 5 years CDMO 4 years had a positive operating cash flow.
CDMO Yearly Net Income VS EBIT VS OCF VS FCFCDMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • CDMO has a Return On Assets of -47.00%. This is comparable to the rest of the industry: CDMO outperforms 48.85% of its industry peers.
  • CDMO has a worse Return On Equity (-339.34%) than 76.46% of its industry peers.
Industry RankSector Rank
ROA -47%
ROE -339.34%
ROIC N/A
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
CDMO Yearly ROA, ROE, ROICCDMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

  • Looking at the Gross Margin, with a value of 7.68%, CDMO is in the better half of the industry, outperforming 73.81% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CDMO has declined.
  • The Profit Margin and Operating Margin are not available for CDMO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
CDMO Yearly Profit, Operating, Gross MarginsCDMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. CDMO Health Analysis

2.1 Basic Checks

  • CDMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CDMO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CDMO has been increased compared to 5 years ago.
  • CDMO has a worse debt/assets ratio than last year.
CDMO Yearly Shares OutstandingCDMO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CDMO Yearly Total Debt VS Total AssetsCDMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -0.51, we must say that CDMO is in the distress zone and has some risk of bankruptcy.
  • CDMO's Altman-Z score of -0.51 is fine compared to the rest of the industry. CDMO outperforms 61.95% of its industry peers.
  • CDMO has a Debt/Equity ratio of 3.58. This is a high value indicating a heavy dependency on external financing.
  • CDMO has a worse Debt to Equity ratio (3.58) than 84.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.58
Debt/FCF N/A
Altman-Z -0.51
ROIC/WACCN/A
WACC8.72%
CDMO Yearly LT Debt VS Equity VS FCFCDMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • CDMO has a Current Ratio of 1.30. This is a normal value and indicates that CDMO is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of CDMO (1.30) is worse than 83.89% of its industry peers.
  • CDMO has a Quick Ratio of 1.30. This is a bad value and indicates that CDMO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of CDMO (0.92) is worse than 87.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.92
CDMO Yearly Current Assets VS Current LiabilitesCDMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CDMO Growth Analysis

3.1 Past

  • The earnings per share for CDMO have decreased strongly by -1305.88% in the last year.
  • The Revenue for CDMO has decreased by -15.80% in the past year. This is quite bad
  • Measured over the past years, CDMO shows a very strong growth in Revenue. The Revenue has been growing by 21.15% on average per year.
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%

3.2 Future

  • Based on estimates for the next years, CDMO will show a very strong growth in Earnings Per Share. The EPS will grow by 27.71% on average per year.
  • Based on estimates for the next years, CDMO will show a very strong growth in Revenue. The Revenue will grow by 22.14% on average per year.
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CDMO Yearly Revenue VS EstimatesCDMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
CDMO Yearly EPS VS EstimatesCDMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. CDMO Valuation Analysis

4.1 Price/Earnings Ratio

  • CDMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDMO Price Earnings VS Forward Price EarningsCDMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDMO Per share dataCDMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CDMO's earnings are expected to grow with 27.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.79%
EPS Next 3Y27.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CDMO Dividend Analysis

5.1 Amount

  • CDMO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CDMO Fundamentals: All Metrics, Ratios and Statistics

AVID BIOSERVICES INC

NASDAQ:CDMO (2/4/2025, 8:00:02 PM)

12.49

+0.01 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-10
Earnings (Next)04-22
Inst Owners105.25%
Inst Owner Change0%
Ins Owners0.95%
Ins Owner Change0%
Market Cap801.11M
Revenue(TTM)150.44M
Net Income(TTM)-152.05M
Analysts74.55
Price Target12.75 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-92.85%
Min EPS beat(2)-125.28%
Max EPS beat(2)-60.43%
EPS beat(4)0
Avg EPS beat(4)-1306.42%
Min EPS beat(4)-4971.9%
Max EPS beat(4)-60.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-3.38%
Max Revenue beat(2)-2.89%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-3.38%
Max Revenue beat(4)-0.02%
Revenue beat(8)3
Avg Revenue beat(8)-3.35%
Revenue beat(12)7
Avg Revenue beat(12)0.75%
Revenue beat(16)11
Avg Revenue beat(16)3.84%
PT rev (1m)0%
PT rev (3m)-7.41%
EPS NQ rev (1m)-9.09%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-1.69%
EPS NY rev (3m)-1.69%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.32
P/FCF N/A
P/OCF 152.36
P/B 17.88
P/tB 17.88
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.08
OCFY0.66%
SpS2.35
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -47%
ROE -339.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.68%
FCFM N/A
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 3.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 119.78%
Cap/Sales 9.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 0.92
Altman-Z -0.51
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)874.1%
Cap/Depr(5y)606.28%
Cap/Sales(3y)40.63%
Cap/Sales(5y)27.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%
EBIT growth 1Y-69.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year176.36%
EBIT Next 3Y71.06%
EBIT Next 5YN/A
FCF growth 1Y89.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y277.64%
OCF growth 3Y-29.44%
OCF growth 5YN/A

AVID BIOSERVICES INC / CDMO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AVID BIOSERVICES INC (CDMO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CDMO.


What is the valuation status of AVID BIOSERVICES INC (CDMO) stock?

ChartMill assigns a valuation rating of 1 / 10 to AVID BIOSERVICES INC (CDMO). This can be considered as Overvalued.


What is the profitability of CDMO stock?

AVID BIOSERVICES INC (CDMO) has a profitability rating of 2 / 10.


Can you provide the financial health for CDMO stock?

The financial health rating of AVID BIOSERVICES INC (CDMO) is 1 / 10.